Novartis To Payers: Entresto Works Or You Get A Discount
This article was originally published in Scrip
Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.
You may also be interested in...
Laying The Groundwork For Value-Based Healthcare In Europe
Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.
Medicare Risk-Sharing Contracts: A More Feasible Drug Cost Solution?
Duke’s Mark McClellan made a strong pitch for such contracting during a Capitol Hill debate on cost control with Johns Hopkins’ Gerard Anderson.